{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P07288",
      "entity_text" : "PSA",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "Species" : [ "taxonomy:9606" ],
      "TissueType" : [ "tissuelist:TS-0828" ]
    }
  },
  "verbose_text" : "The European Randomized Study of Screening for Prostate Cancer (ERSPC)-based Rotterdam Prostate Cancer Risk Calculator (RPCRC), for instance, reduces the percentage of unnecessary, potentially harmful, and costly transrectal ultrasound systematic biopsy (TRUS-Bx) by +/-33% when using PSA level> = 3.0 ng/mL and RPCRC risk> = 12.5% as cut-off values in the urology outpatient clinic.",
  "reading_complete" : "2020-08-04T11:59:04Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T11:57:23Z",
  "trigger" : "level",
  "evidence" : [ "PSA level" ],
  "pmc_id" : "5861274",
  "score" : 0
}